Wynnewood, PA, United States of America

Christopher C Gallen

This inventor holds 1 USPTO granted patent. Top assignee: Pharmacia & Upjohn Company. Active years: 2005.

IDiyas Innovation Intelligence. (2026). Inventor Profile: Christopher C Gallen. Retrieved from https://idiyas.com/inventor/christopher-c-gallen

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

Calculating rank

Average Co-Inventor Count = 3.0

ph-index = 1

Forward Citations = 34(Granted Patents)


Company Filing History:


Years Active: 2005

Loading Chart...
1 patent (USPTO):Explore Patents

Title: Christopher C. Gallen: Innovator in Neuropharmacology

Introduction

Christopher C. Gallen is a notable inventor based in Wynnewood, Pennsylvania. He has made significant contributions to the field of neuropharmacology, particularly through his innovative research and development of pharmaceutical compositions.

Latest Patents

Christopher C. Gallen holds a patent for "Combinations of reboxetine and neuroleptic agents." This composition aims to enhance therapeutic outcomes in patients by combining these two types of medications. He has 1 patent to his name, showcasing his commitment to advancing medical science.

Career Highlights

Gallen is associated with Pharmacia & Upjohn Company, where he has been instrumental in developing new pharmaceutical solutions. His work focuses on improving treatment options for various neurological conditions, reflecting his dedication to patient care and medical innovation.

Collaborations

Throughout his career, Christopher has collaborated with esteemed colleagues, including Torgny Svensson and Erik Ho Fong Wong. These partnerships have fostered a collaborative environment that encourages the exchange of ideas and expertise in the field of neuropharmacology.

Conclusion

Christopher C. Gallen's contributions to the pharmaceutical industry exemplify the impact of innovative thinking in medicine. His work continues to influence the development of effective treatments for neurological disorders.

Profile summary based on public USPTO records.
Data Sources: USPTO Patent Grant XML, Patent Center, EPO & CIPO • Normalized by IDiyas Innovation Graph. Methodology & provenance architecturePlease report any incorrect information to [email protected]
Loading…